Clinical trials: Interstitial Fibrosis
Idiopathic Pulmonary Fibrosis
Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
The purposes of this study are to assess the efficacy of treatment with pirfenidone 2403 milligrams per day compared with placebo in patients with idiopathic pulmonary fibrosis (IPF)and to assess the safety of treatment with…
- Trial name
- NCT00287729
- Testing
- Pirfenidone
- Where
- United States
- Volunteers
- 344 people
- Sponsor
- Genentech, Inc.
Pulmonary Fibrosis, Hypertension, Pulmonary
Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease that affects an individual's ability to breathe. This study will evaluate the effectiveness of sildenafil, a medication that increases blood flow to the lungs, at…
- Trial name
- STEP-IPF (NCT00517933)
- Testing
- Sildenafil Citrate
- Where
- 13 sites in United States
- Volunteers
- 180 people
- Sponsor
- Duke University
Idiopathic Pulmonary Fibrosis
Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
This is a Phase 3 trial to evaluate the efficacy and safety of 30 milligrams (mg)/kilogram (kg) intravenous (IV) infusions of pamrevlumab administered every 3 weeks as compared to placebo in participants with Idiopathic Pulmonary…
- Trial name
- NCT04419558
- Testing
- Pamrevlumab
- Where
- 157 sites in United States, Argentina and 23 more
- Volunteers
- 372 people
- Sponsor
- Kyntra Bio
Cough, Idiopathic Pulmonary Fibrosis
Efficacy and Safety Study of Orvepitant for Chronic Cough in Patients With Idiopathic Pulmonary Fibrosis
ORV-PF-01 is a two way, placebo controlled, cross-over study, to evaluate the effect of two doses of orvepitant on cough in patients with IPF.
- Trial name
- IPF-COMFORT (NCT05185089)
- Testing
- Orvepitant Maleate
- Where
- 37 sites in United States, Netherlands and 1 more
- Volunteers
- 80 people
- Sponsor
- Nerre Therapeutics Ltd.
Pulmonary Fibrosis
Safety and PK Study of BIBF 1120 in Japanese Patients With IPF: Follow up Study From 1199.31(NCT01136174)
Primary objective of this study is to investigate the long-term tolerability and safety profile of BIBF 1120 on top of pirfenidone treatment in patients with Idiopathic Pulmonary Fibrosis who have completed a prior clinical trial…
- Trial name
- NCT01417156
- Testing
- Nintedanib, Pirfenidoneone
- Where
- 4 sites in Japan
- Volunteers
- 20 people
- Sponsor
- Boehringer Ingelheim
Scleroderma
Safety Evaluation of Dasatinib in Subjects With Scleroderma Pulmonary Fibrosis
The purpose of this study was to evaluate the safety of Dasatininb in the treatment of scleroderma pulmonary interstitial fibrosis.
- Trial name
- NCT00764309
- Testing
- dasatinib
- Where
- 13 sites in United States
- Volunteers
- 47 people
- Sponsor
- Bristol-Myers Squibb
Aplastic Anemia
Danazol for Genetic Bone Marrow and Lung Disorders
Background: Some people have bone marrow and lung disorders that are caused by genetic problems. These problems often involve damage to the ends of the chromosomes that pass down genes. One of these disorders is aplastic anemia.
- Trial name
- NCT01441037
- Testing
- Danazol
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Pulmonary Hypertension, Interstitial Lung Disease
An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE
This is a multicenter, open-label trial to evaluate the safety and efficacy of inhaled treprostinil in subjects with pre-capillary pulmonary hypertension (PH) associated with interstitial lung disease (ILD) including combined…
- Conditions
- Pulmonary Hypertension, Interstitial Lung Disease, Combined Pulmonary Fibrosis and Emphysema
- Trial name
- NCT02633293
- Testing
- Inhaled Treprostinil
- Where
- 92 sites in United States, Puerto Rico
- Volunteers
- 243 people
- Sponsor
- United Therapeutics
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
A Study to Characterize the Disease Behavior of Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Disease (ILD) During the Peri-Diagnostic Period
This international clinical study will enroll participants with a suspected diagnosis of IPF/ILD. This study will characterize the disease behavior of IPF and ILD in the peri-diagnostic period.
- Trial name
- NCT03261037
- Testing
- Spirometry, Accelerometry, 6MWT
- Where
- 37 sites in Canada, France and 4 more
- Volunteers
- 178 people
- Sponsor
- Hoffmann-La Roche
Idiopathic Pulmonary Fibrosis
OASIS-IPF (Idiopathic Pulmonary Fibrosis) Study
Descriptive prospective non-interventional multicenter study based on newly collected data of Idiopathic Pulmonary Fibrosis patients followed-up for one year in secondary care settings (Pulmonology Services)
- Trial name
- NCT03386994
- Where
- 31 sites in Spain
- Volunteers
- 204 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis
Open-Label Study of the Long Term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)
This is an open-label, multi-center, extension study for patients with IPF who complete a qualifying InterMune clinical trial of pirfenidone.
- Trial name
- PIPF-012 (NCT00662038)
- Testing
- pirfenidone
- Where
- United States
- Volunteers
- 1,058 people
- Sponsor
- Genentech, Inc.
Idiopathic Pulmonary Fibrosis
To Assess the Efficacy of the Investigational Products Compared to Placebo in Participants With IPF
A participant- and investigator-blinded, randomized, placebo-controlled, multicenter, platform study to investigate efficacy, safety, and tolerability of various single treatments in participants with idiopathic pulmonary fibrosis
- Trial name
- NCT05497284
- Testing
- LTP001, Standard of Care (SoC)
- Where
- 15 sites in United States, Argentina and 5 more
- Volunteers
- 46 people
- Sponsor
- Novartis Pharmaceuticals
Idiopathic Pulmonary Fibrosis
A Study Based on Medical Records That Looks at the Characteristics of Idiopathic Pulmonary Fibrosis Patients Grouped by the Type of Medication They Are Taking
To understand differences in characteristics of Idiopathic Pulmonary Fibrosis (IPF) patients who are prescribed nintedanib compared to those who are prescribed pirfenidone.
- Trial name
- NCT03958071
- Testing
- Nintedanib, Pirfenidone, Untreated Cohort
- Where
- United States
- Volunteers
- 13,264 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis
A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis
To study the safety and effectiveness of multiple-doses of tralokinumab on pulmonary function in adults with mild to moderate idiopathic pulmonary fibrosis (IPF).
- Trial name
- NCT01629667
- Testing
- Tralokinumab
- Where
- 45 sites in United States, Australia and 4 more
- Volunteers
- 409 people
- Sponsor
- MedImmune LLC
Idiopathic Pulmonary Fibrosis
An Efficacy and Safety Study of BG00011 in Participants With Idiopathic Pulmonary Fibrosis
The primary objective of this study is to evaluate the efficacy of BG00011 compared with placebo in participants with Idiopathic Pulmonary Fibrosis (IPF).
- Trial name
- SPIRIT (NCT03573505)
- Testing
- BG00011
- Where
- 90 sites in United States, Argentina and 15 more
- Volunteers
- 109 people
- Sponsor
- Biogen
Pulmonary Fibrosis, Interstitial Lung Disease
The Study of the Use of Nintedanib in Slowing Lung Disease in Patients With Fibrotic or Non-Fibrotic Interstitial Lung Disease Related to COVID-19
This is a collaborative study between Icahn School of Medicine at Mount Sinai, Boehringer Ingelheim Pharmaceuticals and up to 9 other clinical centers across the US to determine the effect of nintedanib on slowing the rate of…
- Conditions
- Pulmonary Fibrosis, Interstitial Lung Disease, Respiratory Disease
- Trial name
- ENDCOV-I (NCT04619680)
- Testing
- Nintedanib
- Where
- 7 sites in United States
- Volunteers
- 103 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Idiopathic Pulmonary Fibrosis
Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis
The purpose of this study is to determine if study drug (BMS-986020) dose of 600 mg once daily or 600 mg twice daily for 26 weeks compared with placebo will reduce the decline in forced vital capacity (FVC) and will be well…
- Trial name
- NCT01766817
- Testing
- BMS-986020
- Where
- 72 sites in United States, Australia and 4 more
- Volunteers
- 325 people
- Sponsor
- Bristol-Myers Squibb
Idiopathic Pulmonary Fibrosis
Adherence to Nintedanib Among Idiopathic Pulmonary Fibrosis Patients
This is a non-interventional cohort study using existing administrative data from the U.S. Medicare program. This study has two objectives: Identification of adherence trajectories of nintedanib among Idiopathic Pulmonary…
- Trial name
- NCT05022784
- Testing
- Nintedanib
- Where
- United States
- Volunteers
- 1,798 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis
Cough Reduction in IPF With Nalbuphine ER
The main purpose of the study is to evaluate the effect of NAL ER on 24-hour cough frequency using objective digital cough monitoring and to assess safety and tolerability of NAL ER.
- Trial name
- CORAL (NCT05964335)
- Testing
- NAL ER
- Where
- 59 sites in Australia, Canada and 8 more
- Volunteers
- 165 people
- Sponsor
- Trevi Therapeutics
Respiratory Tract Diseases, Lung Diseases
Clinical Trial of Low Dose Oral Interferon Alpha in Idiopathic Pulmonary Fibrosis
The purpose of this study is to determine the possible efficacy of low dose, orally administered interferon alpha in subjects with Idiopathic Pulmonary Fibrosis (IPF).
- Conditions
- Respiratory Tract Diseases, Lung Diseases, Lung Diseases, Interstitial, Pulmonary Fibrosis
- Trial name
- NCT01442779
- Testing
- Interferon alpha oral lozenge
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Texas Tech University Health Sciences Center